Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
115 hedge funds and large institutions have $409M invested in Astria Therapeutics in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
32% more capital invested
Capital invested by funds: $310M → $409M (+$99.1M)
10% more funds holding
Funds holding: 105 → 115 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.44% less ownership
Funds ownership: 101.98% → 99.54% (-2.4%)
15% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 39
19% less call options, than puts
Call options by funds: $327K | Put options by funds: $406K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$2.94M |
| 2 |
Morgan Stanley
New York
|
+$2.29M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$1.03M |
| 4 |
Jane Street
New York
|
+$982K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$795K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.83M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.21M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.71M |
| 4 |
BlackRock
New York
|
-$1.42M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.35M |
ATXS Hedge Fund Activity: Q3 2025 in Review
115 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2025, worth a combined $409M — up 32% from $310M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATXS positions and 10 closed out — a net gain of 10 holders — while 33 added to existing stakes and 39 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $2.94M. The largest seller was Fidelity Investments, cutting an estimated $8.83M.
- 115 institutional investors held Astria Therapeutics (ATXS) as of Q3 2025, up from 105 in Q2 2025.
- Funds reported $409M of Astria Therapeutics stock for Q3 2025, up 32% quarter-over-quarter.
- 20 funds opened new Astria Therapeutics positions in Q3 2025 and 10 closed out, a net change of +10 holders.
- The largest Astria Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $2.94M added.
- The largest Astria Therapeutics seller in Q3 2025 was Fidelity Investments, an estimated $8.83M sold.
Based on aggregated 13F filings for Q3 2025.